Pfizer and Mylan have entered an exclusive long-term strategic collaboration to develop, manufacture, distribute and market generic drugs in Japan. Pfizer is responsible for the commercialization of the combined generics portfolio, managing a combined marketing and sales effort. Mylan is responsible for managing operations, including R&D and manufacturing. The collaboration will include a portfolio of more than 350 marketed products across a range of therapeutic areas, as well as more than 125 additional products in development. Products included in the collaboration will be sold under the Pfizer brand with joint labeling.
 
“We are pleased with the opportunity to collaborate with Mylan to meet the ever-growing demand for high-quality generics in Japan. We believe this collaboration will enable both companies to effectively build upon each other’s core capabilities to help meet the needs of more patients and customers in Japan than ever before,” said Albert Bourla, president and general manager of Pfizer’s Established Products Business Unit.
 
Mylan’s chief executive officer, Heather Bresch, said, “We are very excited to have the opportunity to be partnering with Pfizer to build upon our existing assets and drive an even stronger, more sustainable generics business in Japan — one which will be well-positioned to take advantage of anticipated growth in generic utilization in this market and other significant growth opportunities. As a leading global biopharmaceutical company and a leader in the Japanese market, we expect Pfizer will bring significant benefits to the collaboration, particularly in the commercialization of products, and will complement the strengths of our existing Mylan business.”

Pfizer and Mylan will each continue to operate independently in Japan, but will collaborate on current and future generic products, sharing the costs and profits under the collaboration. The transaction is subject to certain closing conditions. Financial terms were not disclosed.